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ABSTRACT
While the adverse health risks associated with smoking have been well-documented, few
studies have examined the cardiovascular outcomes associated with secondhand smoking. The
purpose of the study was to assess the distributions and association of cardiovascular diseases
(CVDs) in nonsmokers exposed to secondhand smoke (SHS). Data were extracted from the
National Health and Nutrition Examination Survey (NHANES) 2015-2016 cycle. Self-reported
smoking status and cotinine levels were used to identify exposure groups (smokers, nonsmokers,
and secondhand smokers), and medical history of several cardiovascular diseases such as
coronary heart diseases and stroke were also collected via self-report survey. The association
between exposure to SHS and seven cardiovascular outcomes were analyzed using chi-square
analysis and odd ratios (OR) with 95% confidence intervals (CIs) were calculated using two
logistic regression models. The data included 5,709 subjects including 18.5% smokers, 23.6%
secondhand smokers, and 57.9% nonsmokers. There was statistically significant association
between exposure to SHS and only two out of seven cardiovascular outcomes, hypertension (OR
1.554, 95% CI [1.066, 2.265]) and cholesterol levels (OR 1.213, 95% CI [1.017, 1.446]). This
study is one of the first to determine an association between SHS and seven cardiovascular
outcomes, thus highlighting the importance of reducing SHS exposure and can be used for
further research on SHS and cardiovascular health.
Key words: Cardiovascular disease, cardiovascular health, secondhand smoke, passive
smoking, environmental tobacco smoke, hypertension, cholesterol levels.
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INTRODUCTION
Statement of the Problem
According to the World Health Organization (WHO), over one-third of all people are
regularly exposed to secondhand smoke (SHS) across the world, including 40% of children, 33%
of male nonsmokers, and 35% of female nonsmokers (World Health Organization, n.d.).
Additionally, the Centers for Disease Control and Prevention (CDC) estimated that, even with
tobacco bans in public places, 58 million people—roughly one in four nonsmokers—were
exposed to SHS during 2013-2014 (Tsai et al., 2018). Previous work has shown that more than
20 million Americans have died due to causes related to SHS, including nearly 2.5 million who
died due to lung cancer or cardiovascular diseases (CVDs) (Tsai et al., 2018; U.S. Department of
Health and Human Services, 2014). Exposure to SHS also increase the risk of stroke by 20% to
30%. Additionally, SHS may even lead to reproductive concerns, such as low birth weight (U.S.
Department of Health and Human Services, 2014). As nonsmokers exposed to SHS are more
likely to develop these outcomes, it is critical to understand the relation between SHS exposure
and CVDs.
Also known as passive smoking or environmental tobacco smoke, SHS, is the inhalation
of burning tobacco products—such as cigarettes, pipes, hookah, or e-cigarettes by people other
than the active smoker (Centers for Disease Control and Prevention, 2018c; U.S. Department of
Health and Human Services, 2014). Secondhand smoke is a known cause of many diseases in
adults and children, including stroke, nasal irritation, lung cancer, and CVDs. Exposure to SHS
was highest among people who have respiratory diseases, CVDs, and cancer (Asfar et al., 2019).
Additionally, children aged 3 to 11 years have the highest exposure to SHS, including 67.9% of
non-Hispanic blacks, 37.2% of non-Hispanic whites, and 29.9% of Mexican Americans (Homa
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et al., 2015). Few studies have examined the exposure to SHS and different biomarkers of CVDs,
but results suggest a direct relation (Saxena, Liang, Muhammad-Kah, & Sarkar, 2017; Venn &
Britton, 2007). None of these studies, however, examined the different types of CVDs in
nonsmokers exposed to SHS, which would be critical, given the fact that heart diseases are the
leading cause of death in the United States (CDC). Therefore, the purpose of this study is to
assess the distribution of CVDs in nonsmokers exposed to SHS. It is hypothesized that
individuals who are nonsmokers, but exposed to secondhand smoke, will have similar likelihood
of having CVDs compared to firsthand smokers. The following question will guide the study’s
analysis:
Do nonsmokers who have an exposure to SHS have similar likelihood of developing
CVDs compared to firsthand smokers?
Literature Review
Secondhand Smoke: Overview
Although smoking among U.S. adults has declined from 20.9% in 2005 to 15.5% in
2016, it is still an ongoing epidemic in the United States (Centers for Disease Control and
Prevention, 2018d). According to the Surgeon General, if smoking rates remain unchanged, 5.6
million Americans younger than 18 years of age are projected to die due to smoking-related
illness (U.S. Department of Health and Human Services, 2014).
Exposure to SHS is harmful to health and has been linked to several fatal illnesses among
infants and adults. Although exposure to SHS has declined by over 50% (25.3% in 2011-2012
from 52.5% in 1999-2000), 58 million people—roughly one in four nonsmokers—were still
exposed to SHS during 2013-2014 (Homa et al., 2015; Tsai et al., 2018; U.S. Department of
Health and Human Services, 2014). In 2006, more than 42,000 Americans died from illnesses
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related to SHS exposure, including more than 41,000 adults and nearly 900 infants (Max, Sung,
& Shi, 2012). Additionally, exposure to SHS causes significantly more death due to CVDs than
due to lung cancer (U.S. Department of Health and Human Services, 2014). In 2005-2009, 32%
of all deaths from CHD were attributed to smoking and exposure to SHS (U.S. Department of
Health and Human Services, 2014). Since there is still a large number of people exposed to SHS
and are more likely to develop CVDs compared to unexposed individuals, more research
assessing CVDs in nonsmokers who are exposed to SHS is warranted.
Secondhand Smoke: Related Conditions
While SHS does not have the same elevated risk levels as firsthand smoking, SHS
exposure is still not risk free. According to report of the Surgeon General, in adults, exposure to
SHS can increase the risk of stroke, nasal irritation, lung cancer, coronary heart disease (CHD),
and reproductive effect in women such as lower low birthweight (U.S. Department of Health and
Human Services, 2014). The CDC also states that nonsmokers who are exposed to SHS increase
their risk for developing lung cancer by 20% to 30% and SHS causes more than 7,300 lung
cancer–related deaths each year in the United States (Centers for Disease Control and
Prevention, 2018a).
Moreover, nonsmokers who are exposed to SHS increase their risk of developing CVDs
by 25% to 30%, leading to approximately 34,000 premature deaths from heart diseases every
year in the United States (Centers for Disease Control and Prevention, 2018a). Also, inhaling
SHS can have immediate effects on blood platelets and the lining of blood vessels since
individuals exposed to SHS are still inhaling many types of toxins, which increase the risk of
having heart attack (Centers for Disease Control and Prevention, 2018a). People exposed to SHS
share similar risks with smokers in developing CVDs, which can be expensive and fatal if not
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diagnosed and treated early (U.S. Department of Health and Human Services, 2014).
Unfortunately, many people exposed to SHS are not aware of their increased risk of developing
CVDs and, thus, more research assessing the relation between CVDs and exposure to SHS in
nonsmokers is warranted.
Evaluation Exposure to Secondhand Smoke Using Biological Markers
Tobacco smoke consists of thousands of chemicals, including carbon dioxide, carbon
monoxide, nicotine, carbonyls, hydrocarbons, nitrogen oxides, pyridines, and ammonia
("Evaluating Exposure to Secondhand Smoke," 2010). Nonsmokers exposed to SHS are
subjected to two components of SHS: side-stream smoke (85%), which is the smoke emerging
from the burning tip of the cigarette, and main-stream smoke (15%), which is the smoke inhaled
by a smoker when puffing on a cigarette (Kritz, Schmid, & Sinzinger, 1995). Compounds about
three to four times more toxic are emitted through side-stream compared to main-stream smoke
("Evaluating Exposure to Secondhand Smoke," 2010; Schick & Glantz, 2005). Additionally,
both side- and main-stream smoke are capable of generating oxidative stress–inducing
chemicals—such as acrolein, xanthine oxidase, and oxides of nitrogen, which may mediate many
of the smoke effects on the cardiovascular system ("Experimental Studies Relevant to the
Pathophysiology of Secondhand Smoke," 2010). Thus, the toxicity that nonsmokers are exposed
to via SHS can leads to increased risk of different CVDs.
Nicotine is present in all tobacco products, as well as in some foods although at very low
concentrations (Benowitz, 1999). Once nicotine enters the body, it will be converted to cotinine,
which is then converted to trans-3'-hydroxycotinine by the hepatic enzyme cytochrome P450
2A6 (Hukkanen, Jacob, & Benowitz, 2005). About 70% to 80% of nicotine is converted to
cotinine, which makes it the primary metabolite ("Evaluating Exposure to Secondhand Smoke,"
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2010; Hukkanen et al., 2005). Cotinine can be measured in blood, saliva, urine, and other
biologic fluids. The average half-life of cotinine (16 hours) in plasma is 8 times longer than
nicotine (2 hours). Additionally, the concentrations of cotinine in blood and saliva are highly
similar. However, urinary cotinine concentrations are four to five times higher than those in
blood or saliva, which makes urine a more sensitive matrix for detection of low exposure of
cotinine (Benowitz, Bernert, Caraballo, Holiday, & Wang, 2009; Hukkanen et al., 2005).
Therefore, cotinine concentrations are more stable than nicotine due to the longer half-life and
the ability to measure it in different body fluids, making it the preferred biomarker of smoke
exposure to SHS and to differentiate smokers from nonsmokers.
Cardiovascular Diseases Due to Secondhand Smoke Exposure
Effects of Secondhand Smoke at the Cellular Level
Endothelial Dysfunction
The normal function of endothelial cells is to promote vasodilation and inhibit thrombosis
and atherosclerosis, which is mediated by the release of nitric oxide (NO) (Glantz & Parmley,
2001). However, a dysfunction in the endothelial cells can lead to the development of
atherosclerosis—a build-up of cholesterol plaque in the arterial walls. Otsuka and colleagues
(2001) conducted a cross-sectional study to determine the acute effects of SHS on coronary
circulation in healthy nonsmokers, Japanese men, found that only 30 minutes of exposure to SHS
can cause endothelial dysfunction of the coronary circulation in nonsmokers (Otsuka et al.,
2001). Additionally, there was a similar endothelial-dependent vasodilation impairment between
active smokers and people who had exposure to SHS.
Similar to the previous study by Otuska et al., (2001), a more recent study investigated
endothelial cells and the flow-mediated dilation by sampling endothelial cells in three groups: 1)
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active smokers; 2) individuals exposed to SHS; and 3) nonsmokers. The study confirmed that
SHS exposure increases vascular inflammation and reduces endothelial NO synthase to the same
levels as an active smoker (Adams et al., 2015). Even though these studies were published more
than ten years apart, they indicate direct toxic effects of SHS exposure on the endothelial cells,
which can lead to more serious types of CVDs.
Inflammation
Tobacco smoke produces systemic inflammation via an increase of oxidative stress
mediators and the reduction of NO bioavailability (Ambrose & Barua, 2004). There are many
biological markers for inflammation, including C reactive protein (CRP), white blood cell
(WBC) count, fibrinogen, and blood viscosity (Ambrose & Barua, 2004; Jefferis et al., 2010).
One of the essential biological markers for inflammation for CVDs is CRP—a hepatic protein
produced in response to acute and chronic inflammation. At population level, a high-sensitive
CRP (hs-CRP) test is used to assess CVD risk.
Multiple studies have examined the relation between SHS and inflammation, and all of
them have shown a positive correlation between SHS and inflammation (Jefferis et al., 2010;
Venn & Britton, 2007). For example, in a cross-sectional, population-based study of more than
5,000 participants, investigators looked at multiple biological markers for inflammation,
including CRP, WBC count, triglycerides, fibrinogen, and blood viscosity (Jefferis et al., 2010).
Compared to nonsmokers, participants who were current smokers or nonsmokers with SHS
exposure had higher circulating levels of CRP, WBC count, triglycerides, and fibrinogen. The
authors concluded that inflammatory markers related to CVDs risk showed an independent
association with SHS exposure in a similar way as active smoking (Jefferis et al., 2010).
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Furthermore, using data from the third National Health and Nutrition Examination
Survey (NHANES III), Venn & Britton (2007) examined the relationship between SHS and
inflammation levels using participants’ cotinine levels. They found that participants exposed to a
small amount of SHS had increased levels of two biological markers for CVDs, which were
fibrinogen and homocysteine (Venn & Britton, 2007). However, there was no evidence that CRP
increased in relation to cotinine levels (Venn & Britton, 2007). Yet, a different study that also
used NHANES III data to examine the relation between SHS and CRP levels in never smokers 618 years old found that there was an association between the increase in serum cotinine and an
increase in CRP (Wilkinson, Lee, & Arheart, 2007). In conclusion, there is strong evidence of a
relation between exposure to SHS and an increase in CVD inflammation biomarkers.
Lipid Profile
Secondhand smoke exposure may promote atherosclerosis due to its effects on
endothelial cells and lipid profile. In an animal study, investigators used a mouse model and
smoking systems that closely simulated exposure of SHS. The mice had moderate lipid levels
that mimicked human lipid levels that led to atherosclerosis plaque formation. They found that
exposure to SHS decreased plasma high-density lipoprotein (HDL) cholesterol levels in the
blood and decreased the ratio between HDL and low-density lipoprotein (LDL) cholesterol, HDL
cholesterol and triglycerides, and HDL cholesterol and total cholesterol (Yuan et al., 2007). In a
similar study with humans, investigators took blood samples from 10 nonsmokers (5 male and 5
female) with normal lipid levels. Then subjects were exposed to 30 minutes of SHS. They found
that exposure to SHS accelerated lipid peroxidation and LDL cholesterol modification.
Additionally, there was an association between an increased accumulation of LDL cholesterol in
human macrophages (Valkonen & Kuusi, 1998).
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Furthermore, a study examined 12 healthy, nonsmoker males to determine the influence
of a 6-hour exposure to SHS on lipoprotein levels. Baseline blood samples were drawn before
SHS exposure and after 6, 8, 16, and 24 hours of SHS exposure. Investigators found that
exposure to SHS can reduce HDL cholesterol levels by 18%. Additionally, there was a negative
impact on HDL cholesterol levels and remained depressed for at least 24 hours (Moffatt,
Chelland, Pecott, & Stamford, 2004). Therefore, short-term exposure to SHS led to inflammation
and an imbalance in the lipid profile, which leads to lipid accumulation in the liver and the blood
vessels of the heart that leads to more severe types of CVDs.
Thrombosis
Thrombosis is the formation of a thrombus—a blood clot, within a blood vessel.
Thrombocytes are cell derivatives that circulate in the blood and play a role in thrombosis.
Secondhand smoke exposure can cause alteration in the function of platelets and antithrombotic,
prothrombotic, and fibrinolytic factors (Ambrose & Barua, 2004). Additionally, SHS exposure
may decrease availability of platelet-derived NO and decrease platelet sensitivity to exogenous
NO, leading to increased activation and adhesion (Ambrose & Barua, 2004; Ichiki, Ikeda,
Haramaki, Ueno, & Imaizumi, 1996). Increased platelet adhesion will increase thrombus
formation, which disrupts the endothelium, speed progression of atherosclerosis, and increase
risk of ischemic heart disease (Law & Wald, 2003).
A study by Burghuber et al (1986) concurs with the findings reported by Ambrose &
Baru (2004) regarding platelet sensitivity and SHS exposure. This study had 9 healthy male
nonsmokers sit in a room for 20 minutes where 30 heavy band cigarettes had just been smoked.
Blood was drawn before and 15 minutes after participants had been exposed to SHS.
Investigators found that platelets sensitivity nonsmokers decreased due to SHS exposure.
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Therefore, exposure to SHS decrease platelets sensitivity, which can increase platelets activation
and thrombosis that can leads to more severe types of CVDs such as CHD and stroke.
Hypertension
Secondhand smoke exposure shows multiple effects on blood pressure; however, the
literature suggests these effects may primarily occur in males (Flouris, Metsios, Jamurtas, &
Koutedakis, 2008). For example, in a study that examined the effects of exposure to SHS on
blood pressure, 14 men and 14 women were exposed to a simulated SHS in bar-restaurant
environment for 60 minutes. Even though the study included a small sample size, the investigator
found that systolic blood pressure significantly increased in men but not in women (Flouris et al.,
2008). Similarly, in a study examined the effects of a 60-minute exposure to SHS on blood
pressure and aortic pressure waveform in 10 healthy men, 11 women, and 12 controls (6 men,
6 women). The investigators found that, in men only, there was an association between SHS and
increased brachial and aortic systolic blood pressure after 60 minutes. About half of the blood
pressure increase happened at 15 minutes and it reached steady state after 30 minutes.
Additionally, the authors found an increase in arterial stiffness, which could be the cause of
increased blood pressure. However, brachial and aortic diastolic blood pressure and heart rate did
not change in either male or females subjects (Mahmud & Feely, 2004). Therefore, an acute
exposure to SHS has a deleterious effect on blood pressure in healthy males but not females.
Coronary Heart Disease
Also known as coronary artery disease or ischemic heart disease, CHD is the most
common type of heart disease in the United States, killing more than 365,900 people in 2017.
Additionally, about 18.2 million adults age 20 and older have CHD (Centers for Disease Control
and Prevention, 2019a). Coronary heart disease is caused by plaque buildup in the wall of the
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coronary artery of the heart. Plaque is made up of deposits of cholesterol and overtime it can
become atherosclerosis.
The effect of SHS on the risk of CHD is controversial. Although several meta-analyses
have concluded that exposure to SHS increases the risk of CHD by 25% among nonsmokers, a
study by Enstrom and Kabat (2006) disputed the results of these studies, suggesting that
selection bias of results may have skewed findings (Enstrom & Kabat, 2006). Their study
focused on the United States cohort studies which provided the most available evidence about
the association between CHD and SHS. They concluded that there is about 5% increase risk of
death from CHD in nonsmokers exposed to SHS (Enstrom & Kabat, 2006). Similarly, in a
different meta-analysis that reviewed epidemiological studies published between 1966 and 1998,
He and colleagues (1999) looked at 10 prospective cohort studies and 8 case-control studies on
the association between SHS and CHD. This study found that SHS exposure is associated with a
greater risk of CHD (relative risk [RR] 1.25; 95% confidence interval [CI] [1.17, 1.32])
compared to unexposed nonsmokers. Specifically, there was a, 21% increased risk of CHD in
cohort studies, and a 51% increased risk of CHD case control studies (J. He et al., 1999).
Angina
Also known as angina pectoris and acute coronary syndrome, angina is chest pain or
discomfort that occurs when the heart muscle does not get enough oxygenated blood. It is a
common symptom of CHD, which narrows the blood vessels to limit blood flow to the heart and
increases the risk of a heart attack (National Heart Lung and Blood Institute, n.d.). Early work by
Aronow (1978) examined the association between angina and exposure to SHS in a sample of
ten male patients who experienced exercise-induced angina, after exposure to the smoke of 15
cigarettes within two hours in a ventilated room and unventilated room. The study found that
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exposure to SHS lead subjects to elevated venous carboxyhemoglobin, increased heart rate,
systolic and diastolic blood pressure while resting, and decreased heart rate and systolic blood
pressure at angina. Additionally, the study concluded that exposure to SHS aggravates angina
(Aronow, 1978). However, this is the only study that has been done to examine the association
between angina and exposure to SHS. Thus, it is a reason for more research to be done to
examine SHS and chronic angina.
Heart Attack
Heart attack, also called a myocardial infarction (MI), happens when a part of the
myocardium does not get enough blood. The leading cause of death in the United States is heart
diseases which can lead to heart attack. In the United States, about 805,000 Americans have a
heart attack every year, and about one in five heart attacks is silent—the person is not aware of it
(Centers for Disease Control and Prevention, 2019a). It is unknown, however, the percentage of
heart attacks that may have been a result of SHS, as SHS exposure can cause cellular dysfunction
through endothelial dysfunction, inflammation, and thrombosis, which may lead to more serious
heard diseases, and result in a heart attack.
Based on this findings, results from multiple studies support the suggestion that exposure
to SHS increases the risk of a heart attack across the world (Attard et al., 2017; Iversen,
Jacobsen, & Lochen, 2013). For example, Iversen and collaborators (2013) looked at active and
passive smoking as a risk factor for heart attack in an 11-year follow-up of 11,762 men and
13,206 women using data from the Tromsø Study in Norway. Out of 453 cases of heart attack in
women, 20% of these cases were attributed to SHS. Additionally, the study concluded that
women who are living with a smoker for 30 years or more after the age of 20 had increased risk
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of heart attack by 40% due to SHS. However, there was no effect of living with a smoker in men
(Iversen et al., 2013).
Similarly, the Maltese Acute Myocardial Infarction (MAMI) case-control study examined
423 cases with a first heart attack and 465 population controls. The study used a questionnaire
and morning fasting blood samples to investigate the effect of SHS and the risk of a heart attack.
The study concluded that exposure to SHS increased the risk of heart attack, and reported that
there was a higher risk of heart attack from SHS in the home rather than in public settings
(Attard et al., 2017). These findings suggest that exposure to SHS in nonsmokers does increase
the risk of a heart attack, and that this risk may be particularly high in nonsmokers living in
households with other smokers.
Stroke
Stroke is one of the leading causes of death in the United States. Every year, stroke kills
about 140,000 people in the United States and 8,000 of those deaths due to SHS exposure.
Additionally, about 87% of all strokes are ischemic stroke—when blood flow to the brain is
blocked, usually by a thrombus (Centers for Disease Control and Prevention, 2019c, 2020). The
current literature suggests an increased risk for stroke when there is SHS exposure. For example,
in a national population-based case-control study in China, investigators used the Nationwide
Retrospective Mortality Survey, conducted from 1989 through 1991. The study included
16,205 cases (12,579 with hemorrhagic stroke and 3626 with ischemic stroke). The study
concluded that, compared with nonsmokers without any exposure to SHS, exposure to SHS
significantly increased the likelihood of death by 10% for all strokes (odds ratio [OR] 1.10; 95%
CI [1.05, 1.16]), by 10% for hemorrhagic stroke (OR 1.10; 95% CI [1.04, 1.16]), and by 12% for
ischemic stroke (OR 1.12; 95% CI [1.03, 1.23]), (Hou et al., 2017).
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Furthermore, a meta-analysis included 14 studies involving 30,3134 subjects and
4,050 stroke events, compared to smokers and nonsmokers with exposure to SHS for the risk of
stroke. The study concluded that smokers had an overall significantly increased likelihood of
stroke compared with nonsmokers (OR 1.61; 95% CI [1.34, 1.93]). There was a statically
significant difference by sex among males (OR 1.54; 95% CI [1.11, 2.13]) and in females (OR
1.88; 95% CI [1.45, 2.44]). Additionally, exposure to SHS significantly increased the overall
likelihood of stroke by 45% (OR 1.45; 95% CI [1.0, 2.11]) (Pan et al., 2019). All 14 studies
found that there was an association between both smoking and exposure to SHS with increased
risk of stroke (Pan et al., 2019). Therefore, exposure to SHS in nonsmokers increases the risk of
stroke.
Heart Failure
Heart failure happens when the heart cannot pump enough blood to support other organs
in the body. There are about 6.5 million adults with heart failure in the United States and it costs
the nation about $30.7 billion in 2012 (Centers for Disease Control and Prevention, 2019b).
Multiple studies examined the association of mortality with SHS exposure for patients with heart
failure. For example, in one study that used NHANES III, there was a total of 19,592 adults,
including 572 participants who had a diagnosis of heart failure, included in their analysis. The
study looked at the household SHS exposure and mortality status of participants from the 2011
Public-Use Mortality Linked File. After analysis, the investigators concluded that there was an
association between the household SHS exposure and an increased risk of death among heart
failure patients (X. He, Zhao, He, Dong, & Liu, 2019).
Similarly, in a longitudinal cohort study, a questionnaire and urinary cotinine levels were
used to define people with SHS to examine its impact on heart failure in 197 participants. After a
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median follow up of 4.3 years, the mean mortality rate was 9 deaths per 100 patient-years (95%
CI [8, 11]), and they concluded that SHS exposure is associated with increase in mortality of
patients with heart failure (Psotka, Rushakoff, Glantz, De Marco, & Fleischmann, 2020).
Therefore, exposure to SHS can increase the mortality rates of patients with heart failure but it
does not increase the risk of heart failure itself.
Overall, the literature demonstrates a meaningful relation between exposure to SHS and
CVDs. The present study addresses a gap in the literature by using a larger sample size from a
national survey to generate more generalizable results that pertain to cardiovascular outcomes in
nonsmokers exposed to SHS.
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METHODS
Participants
Data in this study were obtained from the National Health and Nutrition Examination
Survey (NHANES) 2015-2016 cycle, which targeted the noninstitutionalized United States
civilian population and is administrated by the National Center for Health Statistics (NCHS), part
of the CDC. The annual NHANES collects information on a range of topics pertaining to health
using interviews, physical examination, and laboratory work (Centers for Disease Control and
Prevention, 2017). Relevant contents to this study include current and former smoking status,
exposure to SHS, CVDs, disease prevalence, and blood draw used to determine serum cotinine
levels, among other variables.
The sample size completing the annual NHANES interviews is approximately
5,000 individuals of all ages (Centers for Disease Control and Prevention, 2017). Although the
NHANES has collected data since 1960, this study specifically investigated the sample form the
years 2015 to 2016, which had 9,971 persons who completed the interview, among which
9,544 (95.7%) participants completed interview and provided biological specimens. Data
collected from these years are the most recently published data after the change in the initial
sample design that happened in 2011, which implemented NHANES to oversample nonHispanic (NH) Asians. Additionally, the oversample subgroups in the 2015-2016 survey cycle
included: Hispanics, NH black, NH white, and other races, including multiracial backgrounds
(Centers for Disease Control and Prevention, 2018b).
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Procedure
Demographics
The sample population comprised of 13,164 subjects who answered questions on tobacco
usage, had recorded laboratory values for serum cotinine in blood, and answered specific
questions about CVDs. Demographic data included age, gender, and race/ethnicity and were selfreported by participants. For this study, the sample population was categorized by decades,
starting at age 10 up to a last group comprising 80 years old and above. The race/ethnicity
variables were also categorized into six groups: Mexican American, other Hispanic, nonHispanic white, non-Hispanic black, non-Hispanic Asian, and other races, including multi-racial.
Exposure Groups
Participants were divided into three groups: nonsmokers, nonsmokers exposed to SHS,
and current smokers (CS). Nonsmokers responded “no” to the question “During the past 5 days,
including today, did you smoke cigarettes, pipes, cigars, little cigars or cigarillos, water pipes,
hookahs, or e-cigarettes?” and had blood serum cotinine levels 0.050 ng/ml. Participants
exposed to SHS responded “no” to the question “During the past 5 days, including today, did you
smoke cigarettes, pipes, cigars, little cigars or cigarillos, water pipes, hookahs, or e-cigarettes?”
and had blood serum cotinine levels 0.050 ng/ml. Finally, participants were defined as CS if
they responded “yes” to the question “During the past 5 days, including today, did you smoke
cigarettes, pipes, cigars, little cigars or cigarillos, water pipes, hookahs, or e-cigarettes?” and if
they had blood serum cotinine levels 3.0 ng/ml. Participants must have responded to the
questions and have blood serum cotinine levels reported to be considered in this study.
Participants were excluded if they did not answer the questions above or if they did not have a
blood serum cotinine levels reported.
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Blood cotinine levels cut-offs were 0.050 ng/ml for nonsmokers and 0.050 ng/ml for
nonsmokers exposed to SHS. These values were based on methods reported by previous studies
examining blood cotinine levels in nonsmokers and people exposed to SHS (Agarwal, 2009;
Fabry et al., 2011). As for CS, the blood cotinine level cut-off was 3.0 ng/ml based on previous
studies examining blood cotinine levels in CS (Fabry et al., 2011; Saxena et al., 2017).
Outcomes
There were 11 questions assessing CVDs among NHANES respondents, including six
questions from the Blood Pressure & Cholesterol and five questions from the Medical
Conditions questionnaires. All the answers to these questions were binary (yes/no) and selfreported. Participants who refused to answer the questions, were not provided with
questionnaire, or who did not know the answer were excluded from the study. The questions
from Blood Pressure & Cholesterol questionnaire were:
– Have you ever been told by a doctor or other health professional that you had hypertension,
also called high blood pressure?
– Were you told on 2 or more different visits that you had hypertension, also called high blood
pressure?
– Because of your high blood pressure/hypertension, have you ever been told to take prescribed
medicine?
– Are you now taking prescribed medicine for high blood pressure?
– Have you ever been told by a doctor or other health professional that your blood cholesterol
level was high?
– To lower your blood cholesterol, have you ever been told by a doctor or other health
professional to take prescribed medicine?
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The questions from the Medical Conditions questionnaires were:
– Has a doctor or other health professional ever told you that you had congestive heart failure?
– Has a doctor or other health professional ever told you that you had coronary heart disease?
– Has a doctor or other health professional ever told you that you had angina, also called
angina pectoris?
– Has a doctor or other health professional ever told you that you had a heart attack also called
myocardial infarction?
– Has a doctor or other health professional ever told you that you had a stroke?
Statistical Analyses
Data on demographics, blood serum cotinine levels, questionnaire about blood pressure
and cholesterol and medical conditions, were downloaded from the CDC website. Each dataset
was opened and match-merged one-to-one by participant identification number using the
Statistical Analysis System (SAS) (The SAS Institute; Cary, NC) software. The full dataset was
then exported to the Statistical Package for Social Sciences (SPSS) software (The IBM
Corporation; Armonk, NY) for further analyses.
Chi-square tests were performed to examine the responses to the 11 health questions
related to CVD by the three groups of interest (i.e., CS, exposed to SHS, nonsmokers).
Significance level was established at α=.05.
Additionally, ORs with 95% CIs were calculated using two logistic regression models to
estimate the strength of association between exposure to SHS and cardiovascular outcomes.
Model 1 yielded raw ORs and Model 2 was adjusted for gender, race/ethnicity, and age. In both
models, nonsmokers with no exposure to SHS were used as a reference group and Nagelkerke’s
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R2 was reported as a measure of model fit. This coefficient can be interpreted as the percentage
of variance in the CVD outcomes that can be accounted for by the variables in the models.
Ethical Considerations
The NHANES is a publicly available dataset without any identifiable information
available for use by the research community. Therefore, the Institutional Review Board approval
was not necessary for these secondary analyses.
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RESULTS
The sample population comprised of 13,164 subjects who answered questions on tobacco
usage, had recorded laboratory values for serum cotinine in blood, and answered various
questions about CVDs. Of the 13,164 subjects in the dataset, 7,455 (56.6%) were excluded
because they did not complete portions of the questionnaire about tobacco use or CVDs, leaving
5,709 subjects in the analytic sample.
Demographic Characteristics
The demographic data for the study participants is presented in Table 1.
Table 1. Demographic characteristics of the studied population

Demographic
Variables

Gender
Male
Female

Smokers
(N=1054)

Secondhand
smokers
(N=1347)

Nonsmokers
(N=3308)

Total
(N=5709)

n

Col %

n

Col %

n

Col %

n

Col %

652
402

61.9
38.1

661
686

49.1
50.9

1498
1810

45.3
54.7

2811
2898

49.2
50.8

87.88 (2)

322.79
(14)

Age Groups, years
10-19
20-29
30-39
40-49
50-59
60-69
70-79
80 and older

χ2 (df)a

56
191
199
162
200
168
61
17

5.3
18.1
18.9
15.4
19.0
15.9
5.8
1.6

356
206
140
154
142
164
114
71

26.4
15.3
10.4
11.4
10.5
12.2
8.5
5.3

626
350
417
457
419
505
314
220

18.9
10.6
12.6
13.8
12.7
15.3
9.5
6.7

1038
747
756
773
761
837
489
308

18.2
13.1
13.2
13.5
13.3
14.7
8.6
5.4
361.48
(10)

Race/Ethnicity
Mexican126
12.0
190
14.1%
769
American
Other Hispanic
107
10.2
137
10.2
493
NH white
381
36.1
456
33.9
1048
NH black
329
31.2
404
30.0
456
NH Asian
55
5.2
102
7.6
431
Otherb
56
5.3
58
4.3
111
Abbreviations: col, column; df, degrees of freedom; NH, non-Hispanic
aP<0.001 for all χ2 distributions tested.
bIncludes multi-racial
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23.2

1085

14.9
31.7
13.8
13.0
3.4

737
1885
1189
588
225

19.0
12.9
33.0
20.8
10.3
3.9

Among smokers, typical participants were males (61.9%), non-Hispanic whites (36.1%),
in the 50-59 years old (19.0%) and 30-39 years old (18.9%) groups and compared to secondhand
smokers which had typical participants as females (50.9%), non-Hispanic whites (33.9%), in the
10-19 years old (26.4%) and 20-29 years old group (15.3%). While among nonsmokers, typical
participants were females (50.8%), non-Hispanics whites (31.7%), in the 10-19 years old
(18.9%) group. Chi-square tests for all three demographic characteristics showed that these
distributions were statistically significantly different from a distribution that would occur at
random (P<0.001 for the three distributions).
Cardiovascular Outcomes
Chi-square tests results for the distribution of the 11 CVD outcomes by the three smoking
statuses are presented in Table 2. It can be observed that among nonsmokers, nonsmokers
exposed to SHS, and smokers in the sample, there were statistically significantly different
distributions for the outcomes of hypertension (P=0.04 for taking prescription and P<0.001 for
ever been diagnosed), high cholesterol levels (P<0.001), heart failure (P=0.01), and angina
(P=0.006). However, the distribution by smoking groups was not statistically significantly
different for the outcomes of CHD, heart attack, and stroke.
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Table 2. Cardiovascular Outcomes

Ever told you had high blood pressure

5166

χ2 with 2
df
1.674

Told had high blood pressure >2 times

1768

1.969

0.37

Taking prescription for hypertension

1780

6.602

0.04

Now taking prescribed medicine for high blood pressure

1583

20.211

<0.001

Doctor told you -high cholesterol level

5135

27.054

<0.001

Told to take prescription for cholesterol

3809

5.274

0.07

Ever told had congestive heart failure

4662

8.483

0.01

Ever told you had coronary heart disease

4648

0.456

0.80

Ever told you had angina/angina pectoris

4657

10.158

0.006

Ever told you had heart attack

4664

4.273

0.12

Ever told you had a stroke

4668

4.010

0.14

Cardiovascular Outcomes

N

P
0.43

Abbreviation: df, degrees of freedom

Further, we analyzed and tested the chi-square distributions of CVD outcomes by
demographic characteristics. The results are presented in Table 3 for gender, Table 4 for age
groups, and Table 5 for race/ethnicity.
Table 3 displays the chi-square results based on CVD outcomes by gender. There was a
statistically significantly different distribution for males compared to that of females. Males had
a statistically significantly higher distribution in the group exposed to SHS and two measures of
hypertension and high cholesterol while females exposed to SHS only had statistically
significantly higher distribution angina. There were no other statistically significantly different
distributions for the rest of the CVDs analyzed.
Table 4 presents the chi-square results based on CVD outcomes by age groups. There
were statistically significantly different distributions in hypertension, CHD, angina, heart attack,
and stroke in individuals between 50-59 years old. While individuals between 40-49 years old
had statistically significantly different distributions for hypertension, heart failure, angina, and
stroke. The rest of age groups had two to no CVDs as statistically significant.
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Additionally, Table 5 displays the chi-square results based on cardiovascular outcomes
by race/ethnicity groups. Among the six race/ethnicity groups, non-Hispanic blacks tend to have
most CVDs outcomes (4 out of 7 were statistically significant) while non-Hispanic whites tended
to have the second most CVDs outcomes (3 out of 7 were statistically significant) and Mexican
Americans did not have statistically significantly different distribution for any of the seven
CVDs that were examined in this study.
Table 3. Cardiovascular Outcomes by Gender
Cardiovascular Outcomes
Ever told you had high blood pressure
Told had high blood pressure >2 times
Taking prescription for hypertension
Now taking prescribed medicine for high
blood pressure
Doctor told you -high cholesterol level
Told to take prescription for cholesterol
Ever told had congestive heart failure
Ever told you had coronary heart disease
Ever told you had angina/angina pectoris
Ever told you had heart attack
Ever told you had a stroke
Abbreviation: df, degrees of freedom

P

N

2515
856
861
744

Males
χ2 with
2 df
0.695
3.548
2.353
13.578

0.707
0.170
0.308
0.001

2651
912
919
839

2502
1805
2267
2255
2266
2269
2272

29.234
6.455
3.294
0.678
3.098
0.279
3.218

<0.001
0.040
0.193
0.713
0.212
0.870
0.200

2633
2004
2395
2393
2391
2395
2396

N
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Females
χ2 with
2 df
1.604
2.508
2.869
5.066
5.019
3.827
5.244
0.795
7.725
5.519
4.555

P
0.448
0.285
0.238
0.079
0.081
0.148
0.073
0.672
0.021
0.063
0.103

Table 4. Cardiovascular Outcomes by Age Groups

Outcome

N

Ever told you had high
500
blood pressure
Told had high blood
18
pressure >2 times
Taking prescription for
19
hypertension
Now taking prescribed
medicine for high blood
5
pressure
Doctor told you -high
500
cholesterol level
Told to take prescription
171
for cholesterol
Ever told had congestive
0
heart failure
Ever told you had
0
coronary heart disease
Ever told you had
0
angina/angina pectoris
Ever told you had heart
0
attack
Ever told you had a
0
stroke
Abbreviation: df, degrees of freedom

10-19
χ2 with
2 df

P

N

5.170

0.08

747

0.450

0.80

0.262

20-29
χ2 with
2 df

P

N

0.466

0.79

753

58

0.214

0.90

0.89

58

0.110

2.917

0.23

25

1.036

0.60

2.636

30-39
χ2 with 2
df

40-49
χ2 with 2
df

P

N

18.004

<0.001

773

9.088

0.01

143

0.238

0.89

215

0.959

0.62

0.95

143

0.966

0.62

215

7.040

0.03

1.176

0.56

99

0.495

0.78

173

7.364

0.02

746

0.152

0.93

752

4.343

0.14

771

0.607

0.74

0.27

370

3.834

0.15

497

5.174

0.08

624

3.823

0.15

—

—

747

—

—

756

1.630

0.44

773

6.753

0.03

—

—

747

—

—

756

0.808

0.67

771

0.054

0.97

—

—

747

2.63

0.27

755

3.299

0.19

772

7.063

0.03

—

—

747

—

—

755

1.567

0.46

772

4.493

0.10

—

—

747

5.737

0.06

756

1.378

0.50

773

15.933

<0.001
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P

50-59
Outcome
Ever told you had high
blood pressure
Told had high blood
pressure >2 times
Taking prescription for
hypertension
Now taking prescribed
medicine for high blood
pressure
Doctor told you -high
cholesterol level
Told to take prescription
for cholesterol
Ever told had congestive
heart failure
Ever told you had
coronary heart disease
Ever told you had
angina/angina pectoris

60-69

80

70-79

N

χ2 with
2 df

P

N

χ2 with
2 df

P

N

χ2 with
2 df

P

N

χ2 with
2 df

P

761

15.968

<0.001

837

3.576

0.17

489

2.386

0.30

306

3.863

0.14

331

3.158

0.21

498

4.527

0.10

302

0.735

0.69

203

0.483

0.78

331

0.335

0.85

502

4.62

0.10

304

1.711

0.42

208

0.352

0.84

312

0.004

>0.99

476

5.712

0.06

290

1.445

0.48

203

1.199

0.55

750

2.236

0.33

832

3.362

0.19

483

0.435

0.80

301

4.832

0.09

652

0.138

0.93

760

3.072

0.22

455

0.072

0.96

280

0.802

0.67

760

4.540

0.10

834

5.931

0.05

485

15.707

<0.001

307

0.034

0.98

759

8.306

0.02

831

3.085

0.21

481

4.892

0.09

303

1.467

0.48

759

9.995

0.007

836

13.784

0.001

486

0.547

0.76

302

2.102

0.35

13.128

0.001

837

9.013

0.01

488

3.008

0.22

304

1.237

0.54

10.116

0.006

836

1.315

0.52

489

5.743

0.06

307

1.596

0.45

Ever told you had heart
761
attack
Ever told you had a stroke
760
Abbreviation: df, degrees of freedom
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Table 5. Cardiovascular Outcomes by Race
Outcome
Ever told you had high blood pressure
Told had high blood pressure >2 times
Taking prescription for hypertension
Now taking prescribed medicine for high blood
pressure
Doctor told you -high cholesterol level
Told to take prescription for cholesterol
Ever told had congestive heart failure
Ever told you had coronary heart disease
Ever told you had angina/angina pectoris
Ever told you had heart attack
Ever told you had a stroke
Abbreviation: df, degrees of freedom

Outcome
Ever told you had high blood pressure
Told had high blood pressure >2 times
Taking prescription for hypertension
Now taking prescribed medicine for high blood
pressure
Doctor told you -high cholesterol level
Told to take prescription for cholesterol
Ever told had congestive heart failure
Ever told you had coronary heart disease
Ever told you had angina/angina pectoris
Ever told you had heart attack
Ever told you had a stroke
Abbreviation: df, degrees of freedom

Mexican American
χ2 with
P
2 df
968
0.694
0.71
287
5.771
0.06
289
1.704
0.43
251
5.257
0.07

N

Other Hispanic
χ2 with 2 df

P

658
223
223
195

5.188
3.595
17.686
6.911

0.08
0.17
<0.001
0.03

957
614
842
839
843
843
842

654
488
602
601
599
604
604

3.204
2.464
2.697
0.698
0.358
0.568
0.686

0.20
0.29
0.26
0.70
0.84
0.75
0.71

N

1.926
3.465
0.226
2.224
0.850
0.328
4.817

0.38
0.18
0.89
0.33
0.65
0.85
0.09

Non-Hispanic White
χ2 with 2
P
df
1730
1.641
0.44
614
3.373
0.18
620
0.622
0.73
556
6.791
0.03
N

1720
1370
1605
1599
1604
1605
1608

11.264
1.698
0.424
1.503
6.831
0.025
0.608

0.004
0.43
0.81
0.47
0.03
0.99
0.74

Non-Hispanic Black
χ2 with
N
P
2 df
1071
2.309
0.32
447
0.157
0.92
449
2.850
0.24

Non-Hispanic Asian
χ2 with 2
N
P
df
545
0.334
0.85
125
1.185
0.55
126
2.680
0.26

414

7.359

0.02

105

4.171

0.12

62

0.210

0.90

1066
802
957
954
956
956
957

16.584
2.355
8.537
3.952
4.363
9.206
0.351

<0.001
0.31
0.01
0.14
0.11
0.01
0.84

544
394
488
488
488
489
489

4.428
0.712
4.543
3.991
6.493
7.362
0.756

0.11
0.70
0.10
0.14
0.04
0.02
0.69

194
141
168
167
167
167
168

9.859
7.976
3.405
1.075
0.425
0.905
0.786

0.007
0.02
0.18
0.58
0.81
0.64
0.68
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Other, including multiracial
χ2 with 2
N
P
df
194
6.954
0.03
72
0.657
0.72
73
2.571
0.2877

Moreover, ORs with 95% CIs were calculated from logistic regression models for
estimating the effects of exposure to SHS on cardiovascular outcomes.
In Model 1 (Table 6), compared to nonsmokers not exposed to SHS, secondhand smokers
had statistically significant association between exposure to SHS and both hypertension and high
cholesterol levels. Secondhand smokers are 43% more likely to report being told to take
prescribed medication for hypertension and twice as likely to report that they were taking
medication for hypertension during the time they answered the questionnaire. Also, secondhand
smokers are 31% more likely to report that they were told by a physician about having high
cholesterol levels, and 23% more likely to report taking medication for cholesterol levels.
Additionally, Model 1 found a statistically significant association between exposure to SHS and
a reduced likelihood of angina (OR 0.545; 95% CI [0.361, 0.824]) but there was no other
statistically significant likelihood of having other types of CVDs when exposed to SHS.
Furthermore, compared to nonsmokers exposed to SHS, smokers are 41.5% more likely
of having high cholesterol and there was statistically significant association between smoking
and high cholesterol levels. However, there was no statistically significant association between
smoking and any of the other CVD outcomes that were examined through Model 1.
Nagelkerke’s R2 were also calculated for Model 1 which is a measure of the model fit that
range from 0.00 to 1.00. The values in Model 1 were between 0% and 2% which indicate that
there are 98% unaccounted variables for the model’s variability and fit. This model was not a
good fit for the data.
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Table 6. Unadjusted odds ratios and 95% confidence intervals (CIs) for cardiovascular study
outcomes.

Cardiovascular Outcomes

Nagelkerke's
R2

Nonsmokers Exposed to
Secondhand Smoke

Smokers

ORa

95% CI

ORa

95% CI

Ever told you had high blood pressure

0.000

0.908

0.783, 1.052

0.980

0.849, 1.130

Told had high blood pressure >2 times

0.002

0.923

0.682, 1.250

1.172

0.884, 1.553

Taking prescription for hypertension
Now taking prescribed medicine for high
blood pressure
Doctor told you -high cholesterol level

0.007

1.430

1.008, 2.029

0.829

0.557, 1.233

0.021

2.099

1.508, 2.922

1.189

0.831, 1.702

0.007

1.317

1.130, 1.535

1.415

1.129, 1.641

Told to take prescription for cholesterol

0.002

1.229

1.031, 1.467

1.052

0.888, 1.247

Ever told had congestive heart failure

0.006

0.699

0.482, 1.014

0.609

0.426, 0.871

Ever told you had coronary heart disease

0.000

0.905

0.640, 1.281

1.039

0.722, 1.495

Ever told you had angina/angina pectoris

0.009

0.545

0.361, 0.824

1.071

0.641, 1.790

Ever told you had heart attack

0.003

0.719

0.517, 1.000

0.805

0.572, 1.134

Ever told you had a stroke
0.003
0.704
0.495, 1.003
aNonsmokers not exposed to secondhand smoke are the reference group.

0.965

0.652, 1.427

Model 2 (Table 7) adjusted the ORs and 95% CI for CVD study outcomes by gender,
race/ethnicity, and age groups. Compared to nonsmokers not exposed to SHS, secondhand
smokers were 55% more likely to take prescribed medication for hypertension and 21% more
likely having high cholesterol levels. Additionally, secondhand smokers were significantly less
likely to report hypertension, congestive heart failure, CHD, angina, heart attack, and stroke.
Furthermore, compared to nonsmokers exposed to SHS, smokers were 21% more likely of
having high cholesterol and smokers were 43% less likely for reporting heart failure.
Like Model 1, Nagelkerke’s R2 were also calculated for Model 2. However, Model 2 had
a much better model fit compared to Model 1. All the values in Model 2 were between 4% and
32%. Although Model 2 had higher values than Model 1, Nagelkerke’s R2 showed that Model 2
still did not account for 68% of the variables for the model’s variability and fit; however, it is
still considered a moderate fit that improved the fit of Model 1.
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Table 7. Adjusteda odds ratios and 95% confidence intervals (CIs) for CVD study outcomes.

Outcomes

Nonsmokers Exposed to
Secondhand Smoke

Nagelkerke's
R2

Smokers

AORa,b

95% CI

AORa,b

95% CI

Ever told you had high blood pressure

0.314

0.768

0.645, 0.914

0.803

0.677, 0.951

Told had high blood pressure >2 times

0.042

0.921

0.664, 1.278

1.181

0.883, 1.580

Taking prescription for hypertension
Now taking prescribed medicine for high
blood pressure
Doctor told you -high cholesterol level

0.285

1.060

0.697, 1.612

0.698

0.442, 1.102

0.156

1.554

1.066, 2.265

1.098

0.749, 1.610

0.272

1.213

1.017, 1.446

1.206

1.019, 1.428

Told to take prescription for cholesterol

0.324

0.966

0.783, 1.191

0.905

0.742, 1.105

Ever told had congestive heart failure

0.195

0.462

0.307, 0.696

0.568

0.390, 0.828

Ever told you had coronary heart disease

0.231

0.585

0.397, 0.862

0.929

0.632, 1.364

Ever told you had angina/angina pectoris

0.119

0.421

0.269, 0.659

1.007

0.596, 1.699

Ever told you had heart attack

0.201

0.489

0.339, 0.706

0.730

0.509, 1.048

Ever told you had a stroke

0.124

0.543

0.369, 0.798

0.934

0.624, 1.399

aAdjusted

for gender, race/ethnicity, and age groups.

bNonsmokers

not exposed to secondhand smoke are the reference group.
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DISCUSSION
The purpose of this study was to assess the distribution and likelihood of CVDs in
nonsmokers exposed to SHS. It was originally hypothesized that nonsmokers exposed to SHS
would have similar likelihood of having CVDS compared to firsthand smokers. The results
showed that secondhand smokers were significantly more likely to take medication for
hypertension and having high cholesterol levels compared to nonsmokers.
Based on the results adjusted by demographics in Model 2, this study showed that SHS
exposure in self-reported nonsmokers was significantly associated with higher likelihood of
hypertension and cholesterol levels. Both hypertension and cholesterol levels were examined
using two types of questions. While the first set of questions asks participants if they were told
before that they have high blood pressure or high cholesterol levels, the second set of questions
asks participants about medication use for either condition. Results showed that, compared to
nonsmokers not exposed to SHS, secondhand smokers had significantly higher likelihood of
taking prescribed medication for hypertension and having high cholesterol levels. However,
these results were inconsistent with the results of the other questions about hypertension and
cholesterol levels as they showed no statistically significant association between exposure to
SHS and having hypertension (OR 0.921; 95% CI [0.664, 1.612]) or taking medication for high
cholesterol levels (OR 0.966; 95% CI [0.783, 1.191]). Since these answers are self-reported, the
biases associated with self-report cannot be ruled out. On one hand, recall bias—when
participants do not recall specific facts or events related to their medical records—can be a result
of recall error and are common in epidemiology and medical research (Althubaiti, 2016). On the
other hand, social desirability bias may also play a role: participants answer questions how they
think the researcher would like them to answer. Social desirability bias is also ubiquitous in
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epidemiology research especially when researchers are using data based on survey or
questionnaire and do not have a way to know if participants underestimate or overestimate their
answers (Althubaiti, 2016).
Few previous studies have explored the effects of SHS on hypertension, although these
studies are consistent with the our results, they were gender-specific and typically involved a
small sample size (Flouris et al., 2008; Li et al., 2015; Mahmud & Feely, 2004). Also, most of
these studies found that males are more likely to have hypertension than females (Flouris et al.,
2008; Mahmud & Feely, 2004). However, other studies that used larger datasets supported our
results (Kim et al., 2019; Park et al., 2018; Yang et al., 2017). On one hand, Kim and
collaborators (2019), examined the association between SHS exposure and hypertension in
106,268 Korean nonsmokers using both self-reported questionnaire and urine cotinine levels,
similar to our methods. However, they also used an average of two blood pressure measurements
and antihypertensive medication intake to examine the association between SHS and
hypertension. The results concluded that there was a significant association between SHS
exposure and hypertension even with lower levels of frequent and duration of SHS exposure (OR
1.16; 95% CI [1.05, 1.24]) (Kim et al., 2019).
Similarly, Park and collaborators (2018), using data from the Korean National Health and
Nutrition Examination Survey (KNHANES) V 2010-2012, examined the association between
SHS exposure and hypertension in 10,532 (8987 women and 1545 men) never smokers. They
used duration of SHS exposure, blood pressure measurements, and antihypertensive medication
intake to define the exposure groups. They concluded that there was a significant association
between SHS exposure and hypertension in women only (adjusted OR 1.50; 95% CI [1.10,
2.04]) (Park et al., 2018). Additionally, in another study that included more than 5 million
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females along with their husbands from the National Free Pre‐pregnancy Checkup Projects
conducted across 31 provinces in China in 2014 examined the association between SHS
exposure and hypertension. The data were collected using face-to-face interviews and serum
cotinine levels to define the exposure groups. The investigators found statistically significant
association between SHS exposure and hypertension in males (OR 1.28; 95% CI [1.27, 1.30]),
females (OR 1.53; 95% CI [1.30, 1.79]), and mix group of both females and males (OR 1.50;
95% CI [1.36, 1.67]) (Yang et al., 2017). With the literature supporting the results of the present
study, it can be concluded that hypertension is significantly associated with exposure to SHS in
males’ nonsmokers. Thus, nonsmokers who reduce their exposure to SHS reduce their odds of
developing hypertension.
Furthermore, previous studies have examined the impact of SHS exposure on cholesterol
levels in both animal and human studies (Moffatt et al., 2004; Valkonen & Kuusi, 1998; Yuan et
al., 2007). However, similar to the previous studies reporting hypertension outcomes, most
studies examined small sample sizes and showed negative effects of SHS exposure at the cellular
levels that decrease HDL and increase LDL cholesterol (Valkonen & Kuusi, 1998; Yuan et al.,
2007). Although the present study examined self-reported hypercholesterolemia and medication
intake in general, it still adds value to the current literature on the association between SHS
exposure and cholesterol levels due to the analysis of a large sample size of a human population.
The increased likelihood of nonsmokers exposed to SHS to develop high cholesterol levels might
be due to the negative effect of SHS at the cellular level. For example, it has been established
that exposure to SHS can cause endothelial dysfunction which can lead to the development of
atherosclerosis (Glantz & Parmley, 2001; Otsuka et al., 2001). Atherosclerosis is associated with

32

both hypertension and hyperlipidemia (Alexander, 1995). Therefore, exposure to SHS has an
impact at the cellular level that can lead to further advance the severity of different CVD types.
Surprisingly, compared to nonsmokers, secondhand smokers are significantly less likely
of having congestive heart failure CHD, angina, heart attack, and stroke. Although, these results
contradict the current literature regarding stroke and heart attack, they are considered accurate
due to the fact that 26% (N=356) of nonsmokers are in the 10-19 years old and 15% (N= 206) are
in the 20-29 years old group. Typically, these age groups do not develop higher rates of CVDs
such as CHD, angina, heart attack, and stroke. Additionally, our results do not account for the
duration of SHS exposure in each age group. These two conditions make a strong argument for a
dose-response association that cannot be observed in samples with a high proportion of youth, as
it is the case.
Limitations
Several limitations of the study are worth noting. First, there is a possibility of selfreporting biases, such as social desirability and recall biases (Althubaiti, 2016). Second, a large
number of participants were excluded from the study due missing variables on SHS exposure and
CVDs. Third, although the proposed demographic-adjusted Model 2 found some differences
compared to crude Model 1, the overall model fit (Nagelkerke’s R2) was relatively low for both.
This means that there are still other variables unaccounted for both models’ variability and fit.
Those unaccounted variables—such as other health conditions, obesity, genetic composition,
socioeconomic status (SES), and duration of exposure to secondhand smoke—might have further
mediation and moderation effects that were not considered in the models. Therefore, future
studies should consider exploring how other health conditions related to CVDs may attenuate or
increase the magnitude of the association of SHS with CVDs.
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Despite these limitations aside, there are notable strengths in this study. First, to the best
of our knowledge, this is the first study to use the NHANES database to explore the association
between exposure to SHS and cardiovascular outcomes. The NHANES database included a large
sample size which is a representative of the demographics in the United States. Second, the
present study used cotinine measurements to define the three smoker groups including the
nonsmokers exposed to secondhand smoke in addition to self-reported responses. Using the
cotinine levels yields an accurate cut-off value to separate the three smoker groups and reduce
the self-report biases of participants regarding exposure to SHS. Thus, this study further
advances research on secondhand smoke and cardiovascular disease. Last, this study used a solid
and widely accepted methodology to investigate both distributional assumptions through chisquare test and strength of association through logistic regression.
Implications for Research and Policy
Future studies should use matched data from secondary sources that explore exposure to
SHS and cardiovascular outcomes to analyze change over time. This could highlight the effects
of changes in policies that impact smoking bans in public places as there are 12 states in the
United States that do not have 100% smoke-free state law (American Nonsmokers' Rights
Foundation, 2020). Future research should also target the effects of variables not accounted for in
this study, such as other health conditions, obesity, genetic composition, SES, and duration of
exposure to secondhand smoke on the cardiovascular outcomes. This study only determined
whether CVDs were more likely after exposure to SHS but was not able to determine a doseresponse by any of the above variables.
Furthermore, there are 28 states in the United States that have statewide comprehensive
smoke-free law in effect, prohibiting smoking in all indoor areas of workplaces, restaurants, and
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bars (American Lung Association, 2020). Multiple studies have looked at the impact of policies
implication to regulate SHS exposure among nonsmokers in the United States (Farrelly et al.,
2005; Wilson, Shamo, Boynton, & Kiley, 2012). One study based in Michigan, found that urine
cotinine levels among nonsmoking bar employees decreased from 35.9 ng/ml to a level that
could not be measured within 2 months after the have statewide comprehensive smoke-free law
went into effect. Also, the majority of bar employees reported a significant improvement in
general health and in six respiratory symptoms (Wilson et al., 2012). Another study based in
New York, found that salivary cotinine levels among nonsmoking adult workers in restaurants,
bars, and bowling facilities decreased by 85% within 1 year after the smoke-free law went into
effect 2003 (Farrelly et al., 2005). Therefore, it is important to have statewide smoke-free law in
effect in every state in the United States to reduce the SHS exposure among nonsmokers which
will reduce future CVDs.
Implications for Clinical Practice
Considering the strong association between exposure to SHS and both hypertension and
cholesterol levels, clinicians have the opportunity to start educating patients about the impact of
SHS exposure on their health. Currently, clinicians do not use any screening test to examine SHS
exposure. Therefore, we can start screening patients for SHS exposure by including question
about SHS exposure in home, workplaces, and public places. By doing so, clinicians can add this
information to the patients’ medical history and implement preventive measure.
Additionally, clinicians can promote behavior modification plans for nonsmokers
exposed to SHS or have a family history of CVDs. Past research demonstrates that interventions
focused on promoting healthy diets have proven effective for reducing the risk of hypertension
and non-fatal CVDs (Jackson et al., 2020). Additional study concluded that physical training
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have proven to be an effective method for reducing total serum cholesterol levels (Golding,
2013). Therefore, more evidence-based interventions need to be developed to target behavior and
lifestyle modifications. Additional research is needed to identify barriers among different
populations to develop culturally appropriate preventive programs since not all races/ethnicities
are exposed to SHS equally.
Clinician should also consider other variables not accounted for in this study that are
well-known factors for CVDs among nonsmokers exposed to SHS such as other health
conditions, obesity, genetic composition, and duration of exposure to secondhand smoke.
Previous studies have proven that individuals with diabetes mellitus at higher risk if developing
CVDs such as hypertension and high cholesterol levels (Leon & Maddox, 2015). Additionally,
obesity is common in patients with diabetes especially Type II diabetes and is associated with an
increased risk of CVDs (Leon & Maddox, 2015). Thus, other health conditions may affect a
nonsmoker exposed to SHS health outcomes by increasing the risk of having CVDs.

36

CONCLUSION
This study demonstrated a statistically significant distribution and likelihood of
cardiovascular disease after exposure to second-hand smoke. After controlling for age, sex, and
race/ethnicity, nonsmokers exposed to second-hand smoke had a significantly higher likelihood
of reporting hypertension and elevated blood cholesterol levels. Additionally, the present study
addresses a gap in the literature by using a larger sample size from a nationally representative
survey to generate more generalizable results pertaining to cardiovascular outcomes in
nonsmokers exposed to second-hand smoke. This study adds to the literature supporting the need
to develop health interventions to reduce second-hand smoke exposure. Clinicians and
researchers should educate, respectively, patients and populations exposed to second-hand smoke
on meaningful, evidence-based ways to reduce their SHS exposure to reduce the burden of
cardiovascular disease.
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